SEARCH

SEARCH BY CITATION

References

  • 1
    Appel N, Schaller T, Penin F, Bartenschlager R. From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem 2006; 281: 98339836.
  • 2
    Reed KE, Grakoui A, Rice CM. Hepatitis C virus-encoded NS2–3 protease: cleavage-site mutagenesis and requirements for bimolecular cleavage. J Virol 1995; 69: 41274136.
  • 3
    Lorenz IC, Marcotrigiano J, Dentzer TG, Rice CM. Structure of the catalytic domain of the hepatitis C virus NS2–3 protease. Nature 2006; 442: 831835.
  • 4
    Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 1993; 67: 46654675.
  • 5
    Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993; 67: 40174026.
  • 6
    Foy E, Li K, Wang C, Sumpter R, Jr., Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 11451148.
  • 7
    Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 11671172.
  • 8
    Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6: 316.
  • 9
    Bogen SL, Arasappan A, Bennett F, Chen K, Jao E, Liu YT, et al. Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem 2006; 49: 27502757.
  • 10
    Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50: 10131020.
  • 11
    Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186189.
  • 12
    Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 1991; 88: 24512455.
  • 13
    Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 32253229.
  • 14
    Pawlotsky JM. Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol 2006; 299: 261284.
  • 15
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103107.
  • 16
    Eigen M, Biebricher CK. Sequence space and quasispecies distribution. In: DomingoE, AhlquistP, HollandJJ, eds. RNA genetics. Boca Raton, FL: CRC Press, 1998; 211-245.
  • 17
    Domingo E, Martinez-Salas E, Sobrino F, de la Torre JC, Portela A, Ortin J, et al. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance: a review. Gene 1985; 40: 18.
  • 18
    Domingo E, Martin V, Perales C, Grande-Perez A, Garcia-Arriaza J, Arias A. Viruses as quasispecies: biological implications. Curr Top Microbiol Immunol 2006; 299: 5182.
  • 19
    Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006; 439: 344348.
  • 20
    Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339344.
  • 21
    Laskus T, Wilkinson J, Gallegos-Orozco JF, Radkowski M, Adair DM, Nowicki M, et al. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 2004; 127: 764776.
  • 22
    Qin H, Shire NJ, Keenan ED, Rouster SD, Eyster ME, Goedert JJ, et al. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 2005; 105: 533541.
  • 23
    Farci P, Quinti I, Farci S, Alter HJ, Strazzera R, Palomba E, et al. Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci U S A 2006; 103: 84758480.
  • 24
    Quer J, Esteban JI, Cos J, Sauleda S, Ocana L, Martell M, et al. Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection. J Virol 2005; 79: 1513115141.
  • 25
    Ballesteros AL, Franco S, Fuster D, Planas R, Martinez MA, Acosta L, et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. Aids 2004; 18: 5966.
  • 26
    Franco S, Tural C, Clotet B, Martinez MA. Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. Virus Res 2006.
  • 27
    Martinez MA, Clotet B. Genetic screen for monitoring hepatitis C virus NS3 serine protease activity. Antimicrob Agents Chemother 2003; 47: 17601765.
  • 28
    Swofford DL. PAUP*. Phylogenetic analysis using parsimony (*and other methods). Version 4. Sunderland, MA: Sinauer Associates, 2003.
  • 29
    Page RD. TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci 1996; 12: 357358.
  • 30
    Kumar S, Tamura K, Jakobsen IB, Nei M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 2001; 17: 12441245.
  • 31
    Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996; 272: 537542.
  • 32
    Yang Z. PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci 1997; 13: 555556.
  • 33
    Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110113.
  • 34
    Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001; 75: 14371449.
  • 35
    Bandelt HJ, Forster P, Rohl A. Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol 1999; 16: 3748.
  • 36
    DeLano WL. The PyMOL Molecular Graphics System. San Carlos, CA: DeLano Scientific, 2002.
  • 37
    Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, et al. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 1998; 7: 837847.
  • 38
    Yusim K, Richardson R, Tao N, Dalwani A, Agrawal A, Szinger J, et al. Los alamos hepatitis C immunology database. Appl Bioinformatics 2005; 4: 217225.
  • 39
    Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor: reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006; 281: 82058215.
  • 40
    Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70: 2838.
  • 41
    Sices HJ, Kristie TM. A genetic screen for the isolation and characterization of site-specific proteases. Proc Natl Acad Sci U S A 1998; 95: 28282833.
  • 42
    Martinez MA, Cabana M, Parera M, Gutierrez A, Este JA, Clotet B. A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 2000; 44: 11321139.
  • 43
    Cabana M, Fernandez G, Parera M, Clotet B, Martinez MA. Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions. Virology 2002; 300: 7178.
  • 44
    Parera M, Clotet B, Martinez MA. Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease. J Virol 2004; 78: 1405714061.
  • 45
    Parera M, Fernandez G, Clotet B, Martinez MA. HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol BiolEvol 2007; 24: 382387.
  • 46
    Pellerin M, Lopez-Aguirre Y, Penin F, Dhumeaux D, Pawlotsky JM. Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions. J Virol 2004; 78: 46174627.
  • 47
    Thomson JA, Perni RB. Hepatitis C virus NS3–4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Curr Opin Drug Discov Dev 2006; 9: 606617.
  • 48
    Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996; 70: 37633769.
  • 49
    Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997; 71: 66626670.
  • 50
    Stoddart CA, Liegler TJ, Mammano F, Linquist-Stepps VD, Hayden MS, Deeks SG, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001; 7: 712718.
  • 51
    Fernàndez G, Clofet B, Martinez MA. Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J Virol 2007; 81: 24852496.
  • 52
    Weinreich DM, Delaney NF, Depristo MA, Hartl DL. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 2006; 312: 111114.